Prostate cancer management continues to rapidly evolve for men presenting with all stages of disease. In response to the pandemic of overdetection and overtreatment of indolent prostate cancer, active surveillance has become a standard management strategy for many men with low-risk cancers. Many challenges with clinical implementation of active surveillance persist, including optimal selection criteria, surveillance strategies, indicators of disease progression and when further treatment may be warranted. As guest editors of this issue of Translational Andrology and Urology (TAU), we aimed to provide information on the contemporary practice of active surveillance for prostate cancer.
Guest Editors (From left to right)
Marc A. Dall’Era, MD
Associate Professor and Vice Chair of Urology, University of California, Davis, School of Medicine, California, USA
Benjamin J. Davies, MD
Associate Professor of Urology, University of Pittsburgh School of Medicine, Pittsburgh, USA
Scott Eggener, MD
Professor of Surgery; Director, Prostate Cancer Program; Director of Translational and Outcomes Research, Section of Urology, the University of Chicago Medicine, Chicago, USA